This company's documents
Filings
Timely disclosures
- 2026-10-21Notice Regarding the Establishment of an Issuance Limit for New Shares Under the U.S. Shelf Registration System and the Issuance of New Shares Thereunder
- 2026-10-06Notice Regarding Participation in the Maxim Growth Summit 2026 Hosted by Maxim Group, LLC
- 2026-09-30Notice concerning a change in major shareholders
- 2026-09-28Notice Regarding Topline Results from the Phase 2 Clinical Trial of MN-001 (Tipelukast) for Hypertriglyceridemia and Fatty Liver Disease Associated with Type 2 Diabetes Mellitus
- 2026-09-24Notice regarding completion of the last patient’s last visit during the double-blind treatment period of the Phase 2b/3 clinical trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS)
- 2026-09-11Results Briefing Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026
- 2026-09-08Notice Regarding Participation in the 28th Annual Global Conference Hosted by H.C. Wainwright and the 5th Annual Healthcare Conference Hosted by ROTH
- 2026-08-14Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [U.S. GAAP] (Consolidated)
16 more
- 2026-07-17Notice of Filing Submission Regarding an Extension of the Deadline for Filing the Semiannual Report
- 2026-07-15Notice Regarding Progress in the Clinical Trial of MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis (ALS), Funded by the U.S. National Institutes of Health
- 2026-06-30Corporate Governance Report 2026/06/30
- 2026-06-24Notice Regarding Resolutions at the Annual General Meeting of Shareholders
- 2026-06-24Notice Concerning the Issuance of Stock Options (Share Acquisition Rights)
- 2026-06-22Notice Concerning Partial Amendments to the Articles of Incorporation
- 2026-06-08Notice Regarding Patent Approval in the United States for the Treatment of Glioblastoma with Combination Therapy Using MN-166 (Ibudilast) and the PD-1 Antibody Immune Checkpoint Inhibitor
- 2026-05-27Notice regarding completion of the last patient's last visit in the Phase 2 clinical trial of MN-001 (tipelukast) for hypertriglyceridemia and fatty liver disease associated with type 2 diabetes
- 2026-05-26Internet Disclosure Items for the Notice of Convocation of the 2026 Annual General Meeting
- 2026-05-26Notice of Convocation of the 2026 Annual General Meeting
- 2026-05-15Supplementary Explanation of Financial Results for the First Quarter of the Fiscal Year Ending December 2026
- 2026-05-15Summary of Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [U.S. GAAP] (Consolidated)
- 2026-04-28Notice Regarding the Publication of Research Findings on Ibudilast in the International Medical Journal Cancer Research
- 2026-03-23Fiscal Year Ending December 2025 Full-Year Earnings Presentation Materials
- 2026-03-16Notice regarding participation in the 38th Annual Conference hosted by ROTH
- 2026-03-02Notice Regarding Changes in Executive Officers
Data sourcesThe numbers come from filings and market data. Descriptions and extracted research are organized by AI; check the linked sources.
Filings26
Period2016 — 2026
Price15-min delay